Revisiting transdominant-negative proteins in HIV gene therapy

Future Virology

Volumn 8, Issue 8, 2013, Pages 757-768

  Sivakumaran, Haran ^a   Cutillas, Vincent ^a   Harrich, David ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

AIDS; functional cure; gene therapy; HIV; transdominant negative mutant

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BEVIRIMAT; CHIMERIC PROTEIN; COMPLEMENTARY RNA; GAG PROTEIN; GLYCOPROTEIN GP 120; HISTONE DEACETYLASE 1; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE; MUTANT PROTEIN; POL PROTEIN; PROTEIN CHIM3; PROTEIN INI1; PROTEIN REVM10; PROTEIN SAM68; REV PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR SIN3A; TRIPARTITE MOTIF PROTEIN 5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CARBOXY TERMINAL SEQUENCE; CELL BASED GENE THERAPY; DRUG MECHANISM; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; REVIEW; VIRUS DNA CELL DNA INTERACTION; VIRUS MUTANT; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION; WILD TYPE;

EID: 84881468331     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.13.65     Document Type: Review

References (82)

1. Malim MH, Freimuth WW, Liu J et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176(4), 1197-1201 (1992
2. Pearson L, Garcia J, Wu F, Modesti N, Nelson J, Gaynor R. A transdominant tat mutant that inhibits Tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc. Natl Acad. Sci. USA 87(13), 5079-5083 (1990
3. Green M, Ishino M, Loewenstein PM. Mutational analysis of HIV-1 Tat minimal domain peptides: Identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression. Cell 58(1), 215-223 (1989
4. Porcellini S, Alberici L, Gubinelli F et al. The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Blood 113(15), 3443-3452 (2009
5. Walker RC Jr, Khan MA, Kao S, Goila-Gaur R, Miyagi E, Strebel K. Identification of dominant negative human immunodeficiency virus type 1 Vif mutants that interfere with the functional inactivation of APOBEC3G by virus-encoded Vif. J. Virol. 84(10), 5201-5211 (2010
6. Lee SK, Harris J, Swanstrom R. A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J. Virol. 83(17), 8536-8543 (2009
7. Kawada S, Goto T, Haraguchi H, Ono A, Morikawa Y. Dominant negative inhibition of human immunodeficiency virus particle production by the nonmyristoylated form of gag. J. Virol. 82(9), 4384-4399 (2008
8. Müller B, Anders M, Akiyama H et al. HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. J. Biol. Chem. 284(43), 29692-29703 (2009
9. Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO. The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation. Virology 400(1), 137-144 (2010
10. Furuta RA, Shimano R, Ogasawara T et al. HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases. FEBS Lett. 415(2), 231-234 (1997
11. Trono D, Feinberg MB, Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59(1), 113-120 (1989
12. Felber BK, Hadzopoulou-Cladaras M, Cladaras C, Copeland T, Pavlakis GN. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl Acad. Sci. USA 86(5), 1495-1499 (1989
13. Hadzopoulou-Cladaras M, Felber BK, Cladaras C, Athanassopoulos A, Tse A, Pavlakis GN. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 63(3), 1265-1274 (1989
14. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. The HIV-1 Rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338(6212), 254-257 (1989
15. Tiley LS, Malim MH, Tewary HK, Stockley PG, Cullen BR. Identification of a high-affinity RNA-binding site for the human immunodeficiency virus type 1 Rev protein. Proc. Natl Acad. Sci. USA 89(2), 758-762 (1992
16. Malim MH, Cullen BR. HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: Implications for HIV-1 latency. Cell 65(2), 241-248 (1991
17. Fornerod M, Ohno M, Yoshida M, Mattaj IW. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90(6), 1051-1060 (1997
18. Neville M, Stutz F, Lee L, Davis LI, Rosbash M. The importin-beta family member Crm1p bridges the interaction between Rev and the nuclear pore complex during nuclear export. Curr. Biol. 7(10), 767-775 (1997
19. Malim MH, Bohnlein S, Hauber J, Cullen BR. Functional dissection of the HIV-1 Rev trans-activator - Derivation of a trans-dominant repressor of Rev function. Cell 58(1), 205-214 (1989
20. Plavec I, Agarwal M, Ho KE et al. High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of AIDS. Gene Ther. 4(2), 128-139 (1997
21. Woffendin C, Ranga U, Yang Z, Xu L, Nabel GJ. Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl Acad. Sci. USA 93(7), 2889-2894 (1996
22. Bahner I, Sumiyoshi T, Kagoda M et al. Lentiviral vector transduction of a dominant-negative rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication. Mol. Ther. 15(1), 76-85 (2007
23. Bauer G, Valdez P, Kearns K et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89(7), 2259-2267 (1997
24. Bonyhadi ML, Moss K, Voytovich A et al. RevM10-expressing T cells derived in vivo from transduced human hematopoietic stem progenitor cells inhibit human immunodeficiency virus replication. J. Virol. 71(6), 4707-4716 (1997
25. Caputo A, Rossi C, Bozzini R et al. Studies on the effect of the combined expression of anti-tat and anti-rev genes on HIV-1 replication. Gene Ther. 4(4), 288-295 (1997
26. Junker U, Baker J, Kalfoglou CS, Veres G, Kaneshima H, Bohnlein E. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 13(16), 1395-1402 (1997
27. Su L, Lee R, Bonyhadi M et al. Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: Efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro. Blood 89(7), 2283-2290 (1997
28. Podsakoff GM, Engel BC, Carbonaro DA et al. Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34+ cells. Mol. Ther. 12(1), 77-86 (2005
29. Fox BA, Woffendin C, Yang ZY et al. Genetic modification of human peripheral blood lymphocytes with a transdominant negative form of Rev: Safety and toxicity. Hum. Gene Ther. 6(8), 997-1004 (1995
30. Ranga U, Woffendin C, Verma S et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl Acad. Sci. USA 95(3), 1201-1206 (1998
31. Ott M, Geyer M, Zhou Q. The control of HIV transcription: Keeping RNA polymerase II on track. Cell Host Microbe 10(5), 426-435 (2011
32. Ramakrishnan R, Chiang K, Liu H, Budhiraja S, Donahue H, Rice AP. Making a short story long: Regulation of P-TEFb and HIV-1 transcriptional elongation in CD4+ T lymphocytes and macrophages. Biology 1(1), 94-115 (2012
33. Cardarelli F, Serresi M, Albanese A, Bizzarri R, Beltram F. Quantitative analysis of tat peptide binding to import carriers reveals unconventional nuclear transport properties. J. Biol. Chem. 286(14), 12292-12299 (2011
34. Cardarelli F, Serresi M, Bizzarri R, Giacca M, Beltram F. In vivo study of HIV-1 Tat arginine-rich motif unveils its transport properties. Mol. Ther. 15(7), 1313-1322 (2007
35. Cujec TP, Okamoto H, Fujinaga K et al. The HIV transactivator Tat binds to the CDK-activating kinase and activates the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Genes Dev. 11(20), 2645-2657 (1997
36. Weeks KM, Ampe C, Schultz SC, Steitz TA, Crothers DM. Fragments of the HIV-1 Tat protein specifically bind TAR RNA. Science 249(4974), 1281-1285 (1990
37. Li JC, Yim HC, Lau AS. Role of HIV-1 Tat in AIDS pathogenesis: Its effects on cytokine dysregulation and contributions to the pathogenesis of opportunistic infection. AIDS 24(11), 1609-1623 (2010
38. Ulich C, Harrich D, Estes P, Gaynor RB. Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J. Virol. 70(7), 4871-4876 (1996
39. Meredith LW, Sivakumaran H, Major L, Suhrbier A, Harrich D. Potent inhibition of HIV-1 replication by a Tat mutant. PLoS ONE 4(11), e7769 (2009
40. Lin MH, Sivakumaran H, Apolloni A, Wei T, Jans DA, Harrich D. Nullbasic, a potent anti-HIV Tat mutant, induces CRM1-dependent disruption of HIV Rev trafficking. PLoS ONE 7(12), e51466 (2012
41. Apolloni A, Sivakumaran H, Lin MH, Li D, Kershaw MH, Harrich D. A mutant Tat protein provides strong protection from HIV 1 infection in human CD4+ T cells. Hum. Gene Ther. 24(3), 270-282 (2013
42. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418(6898), 646-650 (2002
43. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4(12), e1000231 (2008
44. Norman JM, Mashiba M, Mcnamara LA et al. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol. 12(10), 975-983 (2011
45. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C. T lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Mol. Ther. 12(4), 697-706 (2005
46. Porcellini S, Gubinelli F, Alberici L, Piovani BM, Rizzardi GP, Bovolenta C. Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay. Blood 115(20), 4021-4029 (2010
47. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. Cold Spring Harb. Perspect. Med. 2(7), a006924 (2012
48. Swanstrom R, Willis JW. Synthesis, assembly, and processing of viral proteins. In: Retroviruses. Coffin JM, Huges SH, Varmus HE (Eds). Cold Spring Harbor Laboratory Press, NY, USA, 263-334 (1997
49. Kaplan AH, Zack JA, Knigge M et al. Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67(7), 4050-4055 (1993
50. Waheed AA, Freed EO. HIV type 1 Gag as a target for antiviral therapy. AIDS Res. Hum. Retroviruses 28(1), 54-75 (2012
51. Barlat I, Maurier F, Duchesne M, Guitard E, Tocque B, Schweighoffer F. A role for Sam68 in cell cycle progression antagonized by a spliced variant within the KH domain. J. Biol. Chem. 272(6), 3129-3132 (1997
52. Fumagalli S, Totty NF, Hsuan JJ, Courtneidge SA. A target for Src in mitosis. Nature 368(6474), 871-874 (1994
53. Taylor SJ, Shalloway D. An RNA-binding protein associated with Src through its SH2 and SH3 domains in mitosis. Nature 368(6474), 867-871 (1994
54. Iijima T, Wu K, Witte H et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell 147(7), 1601-1614 (2011
55. Ramakrishnan P, Baltimore D. Sam68 is required for both NF-kappaB activation and apoptosis signaling by the TNF receptor. Mol. Cell 43(2), 167-179 (2011
56. Lukong KE, Richard S. Sam68, the KH domain-containing superSTAR. Biochem. Biophys. Acta 1653(2), 73-86 (2003
57. Bielli P, Busa R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocr. Relat. Cancer 18(4), R91-R102 (2011
58. Reddy TR, Xu W, Mau JK et al. Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev. Nat. Med. 5(6), 635-642 (1999
59. Modem S, Badri KR, Holland TC, Reddy TR. Sam68 is absolutely required for Rev function and HIV-1 production. Nucleic Acids Res. 33(3), 873-879 (2005
60. Reddy TR. A single point mutation in the nuclear localization domain of Sam68 blocks the Rev/RRE-mediated transactivation. Oncogene 19(27), 3110-3114 (2000
61. Soros VB, Carvajal HV, Richard S, Cochrane AW. Inhibition of human immunodeficiency virus type 1 Rev function by a dominant-negative mutant of Sam68 through sequestration of unspliced RNA at perinuclear bundles. J. Virol. 75(17), 8203-8215 (2001
62. Marsh K, Soros V, Cochrane A. Selective translational repression of HIV-1 RNA by Sam68DeltaC occurs by altering PABP1 binding to unspliced viral RNA. Retrovirology 5, 97 (2008
63. Henao-Mejia J, Liu Y, Park IW, Zhang J, Sanford J, He JJ. Suppression of HIV-1 Nef translation by Sam68 mutant-induced stress granules and nef mRNA sequestration. Mol. Cell 33(1), 87-96 (2009
64. Cochrane A. Inhibition of HIV-1 gene expression by Sam68 Delta C: Multiple targets but a common mechanism? Retrovirology 6, 22 (2009
65. Wang W, Cote J, Xue Y et al. Purification and biochemical heterogeneity of the mammalian SWI-SNF complex. EMBO J. 15(19), 5370-5382 (1996
66. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 266(5193), 2002-2006 (1994
67. Morozov A, Yung E, Kalpana GV. Structure-function analysis of integrase interactor 1/hSNF5L1 reveals differential properties of two repeat motifs present in the highly conserved region. Proc. Natl Acad. Sci. USA 95(3), 1120-1125 (1998
68. Turelli P, Doucas V, Craig E et al. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: Interference with early steps of viral replication. Mol. Cell 7(6), 1245-1254 (2001
69. Yung E, Sorin M, Pal A et al. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat. Med. 7(8), 920-926 (2001
70. Das S, Cano J, Kalpana GV. Multimerization and DNA binding properties of INI1/hSNF5 and its functional significance. J. Biol. Chem. 284(30), 19903-19914 (2009
71. Cano J, Kalpana GV. Inhibition of early stages of HIV-1 assembly by INI1/hSNF5 transdominant negative mutant S6. J. Virol. 85(5), 2254-2265 (2011
72. Yung E, Sorin M, Wang EJ, Perumal S, Ott D, Kalpana GV. Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance. J. Virol. 78(5), 2222-2231 (2004
73. Sorin M, Cano J, Das S et al. Recruitment of a SAP18-HDAC1 complex into HIV-1 virions and its requirement for viral replication. PLoS Pathog. 5(6), e1000463 (2009
74. Hassig CA, Tong JK, Fleischer TC et al. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl Acad. Sci. USA 95(7), 3519-3524 (1998
75. Voit RA, McMahon MA, Sawyer SL, Porteus MH. Generation of an HIV resistant T-cell line by targeted 'stacking' of restriction factors. Mol. Ther. 21(4), 786-795 (2013
76. Sawyer SL, Wu LI, Emerman M, Malik HS. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl Acad. Sci. USA 102(8), 2832-2837 (2005
77. Xu H, Svarovskaia ES, Barr R et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl Acad. Sci. USA 101(15), 5652-5657 (2004
78. Giacca M. Clinical applications of gene therapy. In: Gene Therapy. Springer-Verlag Italia, Italy, 139-281 (2010
79. Deeks SG, Autran B, Berkhout B et al. Towards an HIV cure: A global scientific strategy. Nat. Rev. Immunol. 12(8), 607-614 (2012
80. Yu H, Fischer G, Jia G, Reiser J, Park F, Hogan QH. Lentiviral gene transfer into the dorsal root ganglion of adult rats. Mol. Pain 7, 63 (2011
81. Kuroda H, Kutner RH, Bazan NG, Reiser J. Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J. Virol. Methods 157(2), 113-121 (2009
82. Ou W, Marino MP, Suzuki A et al. Specific targeting of human interleukin (IL)-13 receptor alpha2-positive cells with lentiviral vectors displaying IL-13. Hum. Gene Ther. Methods 23(2), 137-147 (2012